Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial

KRd (carfilzomib, lenalidomide, dexamethasone) and D-KRd (with daratumumab) significantly increase rates of measurable residual disease (MRD) negativity compared to VMP 9-Rd 9 in older, fit, transplant-ineligible patients with newly diagnosed multiple myeloma.
Quadruplet therapy (D-KRd) is associated with higher toxicity-related mortality, emphasizing the need for frailty-adapted treatment decisions.
KRd demonstrated a favorable safety profile, especially regarding lower rates of severe neutropenia compared to other arms.